title: Characterization of prostate cancer using T2 mapping at 3T: a multi-scanner study.
abstract: OBJECTIVE
  To assess the prostate T2 value as a predictor of malignancy on two different 3T scanners.
  
  
  METHODS
  Eighty-three pre-prostatectomy multiparametric MRIs were retrospectively evaluated [67 obtained on a General Electric MRI (scanner 1) and 16 on a Philips MRI (scanner 2)]. After correlation with prostatectomy specimens, readers measured the T2 value of regions-of-interest categorized as "cancers", "false positive lesions", or "normal tissue".
  
  
  RESULTS
  On scanner 1, in PZ, cancers had significantly lower T2 values than false positive lesions (P=0.02) and normal tissue (P=2×10(-9)). Gleason≥6 cancers had similar T2 values than false positive lesions and significantly higher T2 values than Gleason≥7 cancers (P=0.009). T2 values corresponding to a 25% and 75% risk of Gleason≥7 malignancy were respectively 132 ms (95% CI: 129-135 ms) and 77 ms (95% CI: 74-81 ms). In TZ, cancers had significantly lower T2 values than normal tissue (P=0.008), but not than false positive findings. Mean T2 values measured on scanner 2 were not significantly different than those measured on scanner 1 for all tissue classes.
  
  
  CONCLUSIONS
  All tested tissue classes had similar mean T2 values on both scanners. In PZ, the T2 value was a significant predictor of Gleason≥7 cancers.
authors.affiliation: Inserm, U1032, LabTau, Lyon 69003, France.
authors.forename: A
authors.initials: A
authors.lastname: Hoang Dinh
authors.affiliation: Inserm, U1032, LabTau, Lyon 69003, France.
authors.forename: R
authors.initials: R
authors.lastname: Souchon
authors.affiliation: Université Joseph-Fourier, laboratoire d'écologie Alpine, BP 53, Grenoble 38041, France; CNRS, UMR 5553, BP 53, Grenoble 38041, France.
authors.forename: C
authors.initials: C
authors.lastname: Melodelima
authors.affiliation: Inserm, U1032, LabTau, Lyon 69003, France; Hospices civils de Lyon, department of urinary and vascular radiology, hôpital Édouard-Herriot, Lyon 69437, France; Université de Lyon, Lyon 69003, France; Université Lyon 1, faculté de médecine Lyon Est, Lyon 69003, France.
authors.forename: F
authors.initials: F
authors.lastname: Bratan
authors.affiliation: Hospices civils de Lyon, department of pathology, hôpital Édouard-Herriot, Lyon, 69437, France.
authors.forename: F
authors.initials: F
authors.lastname: Mège-Lechevallier
authors.affiliation: Université de Lyon, Lyon 69003, France; Université Lyon 1, faculté de médecine Lyon Est, Lyon 69003, France; Hospices civils de Lyon, department of urology, hôpital Édouard-Herriot, Lyon, 69437, France.
authors.forename: M
authors.initials: M
authors.lastname: Colombel
authors.affiliation: Inserm, U1032, LabTau, Lyon 69003, France; Hospices civils de Lyon, department of urinary and vascular radiology, hôpital Édouard-Herriot, Lyon 69437, France; Université de Lyon, Lyon 69003, France; Université Lyon 1, faculté de médecine Lyon Est, Lyon 69003, France. Electronic address: Olivier.rouviere@netcourrier.com.
authors.forename: O
authors.initials: O
authors.lastname: Rouvière
mesh_terms: D000368:Aged; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011471:Prostatic Neoplasms / Q000473:pathology*; D012189:Retrospective Studies
keywords: Prostate cancer; Prostate cancer aggressiveness; Prostate multiparametric MRI; T2